Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.
暂无分享，去创建一个
Michael L. Wang | D. Podoloff | P. Mclaughlin | N. Ueno | W. Erwin | H. Macapinlac | U. Popat | A. Alousi | L. Fayad | R. Champlin | S. Giralt | F. Hagemeister | B. Pro | Alma M Rodriguez | P. Anderlini | C. Hosing | P. Kebriaei | I. Khouri | M. Lima | M. Korbling | R. Saliba | G. Okoroji | F. Maadani | Anne M Stachowiak | R. Valverde